一个STUB1-CHIC2复合体抑制CD8+T细胞以抑制瘤免疫力
Martin W LaFleur1,2, Lauren E Milling3,4, Priyamvada Prathima3,4
1Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. martin_lafleur@hms.harvard.edu.
科学家们发现STUB1是抗瘤CD8+T细胞功能的负调节者. 抑制STUB1-CHIC2通路可以增强CD8+T细胞对癌症的免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 在体内CRISPR在CD8+T细胞中的选已经确定了癌症免疫治疗标.
- 已经注释了基因组的有限部分,表明了新的发现的潜力.
研究的目的:
- 为了确定抗瘤CD8+T细胞功能的新型调节剂.
- 为了研究E3泛素结合酶STUB1在CD8+T细胞介导的抗瘤免疫中的作用.
主要方法:
- 在CD8+ T细胞中进行了体内CRISPR查,这些细胞对小鼠黑色素瘤有反应.
- 评估了CD8+ T细胞中899个基因的功能.
- 利用淘汰模型 (Stub1淘汰CD8+T细胞) 来评估瘤生长控制.
- 研究了涉及STUB1,CHIC2和细胞因子受体表达的分子机制.
主要成果:
- 确定STUB1作为抗瘤CD8+T细胞功能的新型负调节剂.
- 在多个小鼠模型中证明Stub1淘汰CD8+T细胞有效控制瘤生长.
- 阐明了STUB1与CHIC2相互作用,以调节小鼠和人类CD8+T细胞中的细胞因子受体表达.
- 发现互白素-27受体α对于Stub1/Chic2淘汰CD8+T细胞中的瘤生长控制至关重要.
结论:
- 该STUB1-CHIC2复合体调节CD8+ T细胞中的细胞因子受体表达.
- 抑制STUB1-CHIC2通路提供了一种治疗策略,以增强CD8+T细胞介导的抗瘤免疫力.
更多相关视频
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
相关概念视频
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Inhibition of Cdk Activity
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
